Bioactivity:

TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.

CAS nr:

871026-44-7

Purity:

98%

Molecular Weight:

547,96

SMILES:

CC(C)(O)CC(=O)NCCN1C=CC2=C1C(NC1=CC=C(OC3=CC=CC(=C3)C(F)(F)F)C(Cl)=C1)=NC=N2

Formula:

C26H25ClF3N5O3

Pathway:

Tyrosine Kinase/Adaptors,Angiogenesis,MAPK,Chromatin/Epigenetic,Cell Cycle/Checkpoint,Tyrosine Kinase/Adaptors,Angiogenesis,JAK/STAT signaling,JAK/STAT signaling

Target:

HER,HER,MEK,Aurora Kinase,Aurora Kinase,EGFR,EGFR,EGFR,HER